Burling Wealth Partners LLC Purchases Shares of 976 Thermo Fisher Scientific Inc. (NYSE:TMO)

Burling Wealth Partners LLC purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 976 shares of the medical research company's stock, valued at approximately $508,000.

A number of other large investors have also added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Thermo Fisher Scientific by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company's stock worth $17,297,426,000 after acquiring an additional 196,864 shares in the last quarter. Capital World Investors increased its holdings in Thermo Fisher Scientific by 1.1% in the fourth quarter. Capital World Investors now owns 9,430,120 shares of the medical research company's stock worth $4,905,812,000 after purchasing an additional 104,343 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company's stock worth $4,075,540,000 after buying an additional 197,442 shares in the last quarter. Norges Bank acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $3,149,754,000. Finally, Franklin Resources Inc. increased its stake in shares of Thermo Fisher Scientific by 5.7% in the 3rd quarter. Franklin Resources Inc. now owns 4,853,133 shares of the medical research company's stock valued at $2,935,377,000 after acquiring an additional 262,062 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock traded down $2.69 during trading hours on Monday, hitting $421.55. 2,527,222 shares of the company were exchanged, compared to its average volume of 1,746,685. Thermo Fisher Scientific Inc. has a 52-week low of $409.85 and a 52-week high of $627.88. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The firm has a fifty day simple moving average of $487.28 and a 200 day simple moving average of $526.70. The stock has a market capitalization of $159.13 billion, a price-to-earnings ratio of 25.50, a P/E/G ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same quarter in the previous year, the firm posted $5.11 earnings per share. The company's quarterly revenue was up .2% compared to the same quarter last year. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were given a $0.43 dividend. The ex-dividend date was Friday, March 14th. This is a positive change from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.41%. Thermo Fisher Scientific's payout ratio is 10.09%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. The trade was a 25.87 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Stephen Williamson sold 9,825 shares of the company's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $5,753,421.75. Following the sale, the chief financial officer now owns 27,296 shares of the company's stock, valued at approximately $15,984,264.64. The trade was a 26.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 23,900 shares of company stock worth $13,106,062 over the last 90 days. Corporate insiders own 0.33% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. StockNews.com downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Friday. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday. Barclays cut their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price target for the company in a research note on Friday, January 10th. Finally, Citigroup reduced their price objective on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $616.95.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.